Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Accuray develops, manufactures and sells radiation oncology systems that make canc...
Accuray develops, manufactures and sells radiat...
Since Mannatechâs establishment in 1994, the company has pioneered a commitment ...
Since Mannatechâs establishment in 1994, the ...
Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutio...
Allscripts (NASDAQ: MDRX) is a leader in health...
Achieve is a specialty pharmaceutical company committed to advancing cytisinicline...
Achieve is a specialty pharmaceutical company c...
Chiasma is focused on improving the lives of patients who face challenges associat...
Chiasma is focused on improving the lives of pa...
Acer is a pharmaceutical company focused on the acquisition, development and comme...
Acer is a pharmaceutical company focused on the...
Novelion Therapeutics Inc. (âNovelion"), headquartered in Vancouver, British Col...
Novelion Therapeutics Inc. (âNovelion"), head...
Join the National Investor Network and get the latest information with your interests in mind.